LifeSpan Vision Ventures, a Norwalk-headquartered venture capital firm focused on longevity biotechnology, has closed its seventh investment with the addition of Rejuvenation Technologies to its portfolio.
Headquartered in Mountain View, California, Rejuvenation Technologies uses lipid nanoparticles to deliver telomerase mRNA to restore telomere length and tissue regenerative capacity. LifeSpan Vision Ventures’ said this was the latest in its series of strategic investments that included closely tracking funding rounds for companies including LIfT Biosciences, Deciduous Therapeutics and Fauna Bio, with new investments to be announced in the coming weeks.
“We are thrilled to unveil our seventh investment as we continue to advance the longevity field,” said Harry Robb, analyst at LifeSpan Vision Ventures. “Our dedication to extending healthy lives and enabling longer, healthier, and fuller lives for all remains at the core of our mission. We believe that the companies we invest in will play a key role in advancing the next wave of biotech solutions that promise a better future.”
